DSM's 4th-qtr profits up 2%; short of forecasts
Fourth quarter 2007 operating profit at Dutch pharmaceuticals and ingredients firm DSM increased 2% to 190.0 million euros ($278.8 million), shy of the 193.0 million euros predicted by analysts. The firm said that earnings from its nutrition, performance materials and industrial chemicals divisions, which together were 5.4% higher at 190.0 million euros, had helped offset the 17% decline in income from pharmaceuticals.
Sales for the three months ended December 31, 2007, were up 8% to 2.22 billion euros, including a negative 4% impact from currency rates. Pharmaceutical turnover grew 10% to 254.0 million euros, which DSM attributed to an increase in the selling price of its anti-infective products.
Weak dollar/high costs offset by growth
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze